Eastern Hepatobiliary Surgery Hospital
117
11
14
38
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
2.6%
3 terminated/withdrawn out of 117 trials
92.7%
+6.1% vs industry average
10%
12 trials in Phase 3/4
3%
1 of 38 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (117)
Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular Carcinoma
Role: lead
QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors
Role: lead
A Study of Danning Tablet in Patients With Polypoid Lesions of Gallbladder
Role: lead
Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP)
Role: collaborator
Application of Super-Resolution Ultrasound (SRUS) in Liver Tumor
Role: lead
Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer
Role: lead
Effects of Short-term Perioperative Daidzein Intervention on Liver Histopathology in Patients With MASLD
Role: lead
Research on Post-Stroke Anticoagulation Strategies for Atrial Fibrillation Based on Left Atrial Appendage Flow Velocity Measured by Intracardiac Echocardiography (ICE)
Role: collaborator
HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC
Role: lead
Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
Role: lead
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma
Role: lead
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers
Role: lead
A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer
Role: lead
A Study of TIL in Advanced Solid Tumors (DFGD)
Role: collaborator
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
Role: lead
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Role: collaborator
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
Role: collaborator
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Role: collaborator
A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
Role: lead
Bile Omics for Diagnosing Indeterminate Biliary Strictures
Role: collaborator